KDIGO指南解读:成人微小病变肾病和特发性局灶节段性肾小球硬化治疗  

Management of minimal-change disease and idiopathic focal segmental glomerulosclerosis in adults:interpretation of KDIGO guideline

作　　者：陈楠[1] 任红[1] 

机构地区：[1]上海交通大学医学院附属瑞金医院肾脏科,上海200025

出　　处：《中国实用内科杂志》2012年第12期918-920,共3页Chinese Journal of Practical Internal Medicine

基　　金：国家重点基础研究发展计划资助(2012CB517600);国家自然基金资助(81070560);国家自然基金资助(81070568)

摘　　要：微小病变肾病(MCD)和特发性局灶节段性肾小球硬化(FSGS)是成人肾病综合征的常见病理类型。2012年6月发表的改善全球肾脏病预后组织(KDIGO)指南对多种原发及继发性肾小球肾炎的治疗给出了最新意见,对初发、复发、激素依赖和激素抵抗型MCD和FSGS患者的激素使用剂量、疗程及一线免疫抑制剂的选择等给予了建议。本文结合中国患者的特点对该指南关于MCD和FSGS治疗的建议做一解读。Minimalchange disease（MCD） and idiopathic focal segmental glomerulosclerosis （FSGS） are common reasons for nephrotic syndrome in adults. The KDIGO clinical practice guideline for glomerulonephritis published in June,2012 provided the newest recommendations on the treatment of primary and secondary glomerulonephritis. The doses and courses of glucocorticosteroid treatment in the first episode of MCD and FSGS, in relapsed patients, in corticosteroid dependent or corti costeroid resistant patients were suggested. The recommendations for the choice of firstline immunosuppressive agents were given. Here we unscrambled the KDIGO guideline on the treatment of MCD and FSGS in adults regarding the characteristics of Chinese patients.

关 键 词：肾小球肾炎 微小病变肾病 局灶节段性肾小球硬化 KDIGO指南 

分 类 号：R692.31[医药卫生—泌尿科学]